Literature DB >> 16025277

[Lyme borreliosis. Cutaneous manifestation].

H Hofmann1.   

Abstract

Lyme borreliosis is a tick transmitted infectious disease caused by different genospecies of Borrelia burgdorferi sensu lato. In USA only one species B. burgdorferi sensu stricto is prevalent, whereas in Europe at least 5 different pathogenic species could be identified. The most prevalent species are B. afzelii and B. garinii. Infection is not always causing disease. In early infection, a localized skin inflammation, called erythema migrans, occurs around the tick bite, hematogenous dissemination of Borrelia causes flu like symptoms up to meningitis and multiple erythemata migrantia on the skin. In late stage multiple organ systems can be affected, in Europe especially the skin with various forms of acrodermatitis chronica atrophicans, the central and peripheral nervous system, joints and heartmuscle. Lyme borreliosis can be diagnosed by the typical history, the clinical symptoms and the elevated Borrelia specific IgM- and IgG-antibodies in serum and CSF according to the MIQ guidelines, in special cases B. burgdorferi can be cultivated or DNA detected by PCR. Therapy of choice for early infection is oral antibiotics like doxycycline, amoxicillin and cefuroxime for at least 10 days up to 21 days. Late stage infections should be treated for 3-4 weeks. Patients with neurological symptoms should be treated intravenously with ceftriaxone or penicillin G.

Entities:  

Mesh:

Year:  2005        PMID: 16025277     DOI: 10.1007/s00105-005-0995-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  25 in total

Review 1.  Lyme disease.

Authors:  A C Steere
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

2.  Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans.

Authors:  K Weber; V Preac-Mursic; U Neubert; R Thurmayr; P Herzer; B Wilske; G Schierz; W Marget
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

Review 3.  [Therapy of Lyme borreliosis].

Authors:  M D Kramer; D Hassler; H Hofmann; R Wallich; U E Schaible; M M Simon
Journal:  Dtsch Med Wochenschr       Date:  1993-04-02       Impact factor: 0.628

4.  Failure of treatment with cephalexin for Lyme disease.

Authors:  J Nowakowski; D McKenna; R B Nadelman; D Cooper; S Bittker; D Holmgren; C Pavia; R C Johnson; G P Wormser
Journal:  Arch Fam Med       Date:  2000-06

5.  Diagnostic value of PCR for detection of Borrelia burgdorferi in skin biopsy and urine samples from patients with skin borreliosis.

Authors:  S Brettschneider; H Bruckbauer; N Klugbauer; H Hofmann
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

6.  Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis.

Authors:  G Baranton; D Postic; I Saint Girons; P Boerlin; J C Piffaretti; M Assous; P A Grimont
Journal:  Int J Syst Bacteriol       Date:  1992-07

7.  Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis.

Authors:  D M Gross; T Forsthuber; M Tary-Lehmann; C Etling; K Ito; Z A Nagy; J A Field; A C Steere; B T Huber
Journal:  Science       Date:  1998-07-31       Impact factor: 47.728

Review 8.  Lyme borreliosis.

Authors:  Gerold Stanek; Franc Strle
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

9.  Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins.

Authors:  Peter Kraiczy; Jens Hellwage; Christine Skerka; Heiko Becker; Michael Kirschfink; Markus M Simon; Volker Brade; Peter F Zipfel; Reinhard Wallich
Journal:  J Biol Chem       Date:  2003-11-07       Impact factor: 5.157

10.  An epidemiologic study of Lyme disease in southern Sweden.

Authors:  J Berglund; R Eitrem; K Ornstein; A Lindberg; A Ringér; H Elmrud; M Carlsson; A Runehagen; C Svanborg; R Norrby
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  5 in total

1.  [Lyme borreliosis].

Authors:  P Herzer; V Fingerle; H-W Pfister; A Krause
Journal:  Internist (Berl)       Date:  2014-07       Impact factor: 0.743

2.  [Lymphocytoma cutis benigna. Case report of a 9 year old boy].

Authors:  A Steiner; K Stehr; W Rösch
Journal:  Urologe A       Date:  2007-02       Impact factor: 0.639

3.  [Pediatric dermatology. New aspects of bacterial skin infections in children].

Authors:  H Hofmann; C Schnopp
Journal:  Hautarzt       Date:  2009-03       Impact factor: 0.751

Review 4.  [Dermatological symptoms in rheumatology].

Authors:  E Aberer
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

5.  [The variable spectrum of cutaneous Lyme borreliosis. Diagnosis and therapy].

Authors:  H Hofmann
Journal:  Hautarzt       Date:  2012-05       Impact factor: 0.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.